Agoracom: Small Cap Investment - Zenith Epigenetics - Now recruiting: ZEN-3694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Now recruiting: ZEN-3694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)

posted on May 06, 2019 03:19PM

A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)

https://clinicaltrials.gov/ct2/show/NCT03901469

The Zenith/Pfizer trial is now recruiting as of last week. Nashville, TN is open for business!

Also, in case you missed it.....last month the ZEN-3694 and Enzalutamide mCRPC trial updated from "recruiting" to "active, not recruiting." So sounds like they have enrolled what they need and are completing the treatment/follow up of these already enrolled patients. The listing still indicates anticipated completion June 2019.......

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

https://clinicaltrials.gov/ct2/show/NCT02711956

6 Recommendations

Re: Now recruiting: ZEN-3694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)